CAR T-Cell Therapy – Pipeline Insights – 2018
CAR T-cell Therapies
01: Executive Summary
02: Scope of the Report
03: Introduction
3.1 CAR T-cell Therapies – Overview
3.2 CAR T-cell Therapies –Role in the treatment of various types of tumors
04: CAR T-cell Therapies – Pipeline Landscape
4.1 Overview of Pipeline CAR T-cell Therapies
4.2 CAR T-cell Therapies Filed and Phase III Products
4.3 Comparative Analysis
4.4 CAR T-cell Therapies Phase II Products
4.5 Comparative Analysis
4.6 CAR T-cell Therapies Phase I and IND Filed Products
4.7 Comparative Analysis
4.8 CAR T-cell Therapies Discovery and Pre-Clinical Stage Products
4.9 Comparative Analysis
4.10 CAR T-cell Therapies – Discontinued Products
4.11 CAR T-cell Therapies – Dormant Products
05: CAR T-cell Therapies by molecule type
5.1 Small molecule
5.2 Gene Therapies
5.3 Others
06: Comparative Analysis of Marketed and Pipeline CAR T-cell Therapies
07: Key Pipeline Product Profiles
08: Competitive Landscape
8.1 Prominent Vendors:
8.1a Celgene
8.2 Other Prominent Vendors:
8.2a Aeon Therapeutics
8.2b Autolus
8.2c Bellicum
8.2d Beijing Immunochina
8.2e Celyad
8.2f Eureka
8.2g Juno
8.2h Kite
8.2i Intrexon
8.2j Marino Biotechnology
8.2k Pinze Lifetechnology
8.2l Shanghai Unicar-Therapy
8.2m Sinobioway cell Therapy
8.2n Sirtex Medical
8.2o Ziopharm
09: Key News
9.1 Major Mergers and Acquisitions
9.2 Product News (including clinical trial progression updates)